In patients with IgG4-related disease, the serum IgG4 concentration is typically high and often very, very high. Example, elevated up to five or 10 times the upper limit of normal is not unusual ...

Sanofi SNY announced that the European Medicines Agency (EMA) has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for treating IgG4-related disease (IgG4-RD). IgG4 ...

Paris: Sanofi has announced that the European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible ...

The same is true for retroperitoneal fibrosis or Ormand's disease as it was termed when it was described in the 1940s. Retroperitoneal fibrosis is also part of IgG4-related disease.

EMA grants orphan designation to Sanofi’s rilzabrutinib, a reversible covalent BTK inhibitor, for IgG4-related disease: Paris Saturday, August 16, 2025, 09:00 Hrs [IST] Sanofi a ...

This landmark study provides the first population-based estimates of immunoglobulin G4-related disease (IgG4-RD) in the U.S., revealing a 2.5-fold higher mortality risk in IgG4-RD patients versus ...

Background: IgG4-associated autoimmune diseases are systemic diseases affecting multiple organs of the body. Autoimmune pancreatitis, with a prevalence of 2.2 per 100 000 people, is one such disease.

One might point that IgG4-related kidney disease occurred with simple renal cyst in this case. However, simple renal cyst generally arises from proximal origin [9] and she has never detected renal ...

IgG4-related disease is an autoimmune disorder affecting millions and has no established cure. Previous research indicates that T cells, a major component of the immune system, and the ...

SAN DIEGO — Rituximab (Rituxan, Genentech) is a potential treatment option in the multiorgan fibroinflammatory disorder known as immunoglobulin G4-related disease (IgG4), according to ...

Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing ...

Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at ...